Robert Lanza, Chief Scientific Officer at ADVANCED CELL TECHNOLOGY, INC. (ACTC), sold 1,338,490 shares at $0.06 ($80K) on 2012-12-14, disclosed to the SEC on 2012-12-18.
Open-market sale of $80k ACTC by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.06 | 20,000 | $1K | 1.5% |
| 2 | $0.06 | 40,000 | $2K | 3.0% |
| 3 | $0.06 | 43,000 | $3K | 3.2% |
| 4 | $0.06 | 100,000 | $6K | 7.5% |
| 5 | $0.06 | 150,000 | $9K | 11.2% |
| 6 | $0.06 | 440,000 |
| $26K |
| 32.9% |
| 7 | $0.06 | 545,490 | $33K | 40.8% |
| Total | $0.06 avg | 1,338,490 | $80K | 100% |
| Filing → |
| ACTC | SELL | 2012-08-01 | $160K | — | Filing → |
| ACTC | SELL | 2012-01-25 | $1.4M | — | Filing → |
| ACTC | SELL | 2011-09-30 | $109K | — | Filing → |